Literature DB >> 60058

Relative concentrations in human sera of antibodies to cross-reacting and specific antigens of Herpes simplex virus types 1 and 2.

H McClung, P Seth, W E Rawls.   

Abstract

The relative concentrations of antibodies to the cross-reacting and type-specific antigens of herpes simplex virus types 1 and 2 were examined in sera from patients who had been infected by type 1 virus only, by type 2 virus only or by both viruses. Complement-dependent lysis of 51Cr-labeled cells was used to measure antibodies to the surface antigens of cells infected by the viruses. Approximately 80% of the antibody activity was attributable to cross-reacting antigens and 20% to type-specific antigens in sera from patients infected with either type 1 or type 2 virus. Among patients infected with type 1 virus and then type 2 virus, approximately 90% of the antibody activity was to the cross-reacting antigens, 5 to 10% to type 1-specific antigens and little or no antibody to type 2-specific antigens. The observations suggest that infection by type 2 virus in patients with a prior type 1 infection results in an antibody response to the cross-reacting antigens with little or no response to the type-specific antigens.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 60058     DOI: 10.1093/oxfordjournals.aje.a112289

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  12 in total

1.  Latent herpes simplex virus in ganglia of mice after primary infection and reinoculation at a distant site.

Authors:  R J Klein; A E Friedman-Kien; E Brady
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

2.  Prevalence of antibodies to herpes simplex virus types 1 and 2 in pregnant women, and estimated rates of infection.

Authors:  A E Ades; C S Peckham; G E Dale; J M Best; S Jeansson
Journal:  J Epidemiol Community Health       Date:  1989-03       Impact factor: 3.710

3.  Locations of herpes simplex virus type 2 glycoprotein B epitopes recognized by human serum immunoglobulin G antibodies.

Authors:  D E Goade; R Bell; T Yamada; G J Mertz; S Jenison
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

4.  Studies on the neutralizing antibody to herpes simplex virus. II. Quantitative analysis of type specific antibodies in rabbits immunized with both types of virus.

Authors:  M Ohashi; Y Ozaki
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

5.  Type specificity of complement-fixing antibody against herpes simplex virus type 2 AG-4 early antigen in patients with asymptomatic infection.

Authors:  C H Sherlock; R L Ashley; M L Shurtleff; K D Mack; L Corey
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

6.  Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease.

Authors:  Staffan Görander; Ali M Harandi; Madelene Lindqvist; Tomas Bergström; Jan-Åke Liljeqvist
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

7.  Cervical antibodies in patients with oral herpes simplex virus type 1 (HSV-1) infection: local anamnestic responses after genital HSV-2 infection.

Authors:  R Ashley; A Wald; L Corey
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

8.  Detection of immunoglobulin M antibodies to glycoprotein G-2 by western blot (immunoblot) for diagnosis of initial herpes simplex virus type 2 genital infections.

Authors:  D W Ho; P R Field; W L Irving; D R Packham; A L Cunningham
Journal:  J Clin Microbiol       Date:  1993-12       Impact factor: 5.948

9.  Correlation of herpes simplex virus antibody titers and specific lymphocyte stimulation in adult blood donors.

Authors:  H Moser; F Behrens; R Ziegelmaier; J Hilfenhaus; R Mauler
Journal:  J Clin Microbiol       Date:  1981-01       Impact factor: 5.948

10.  Comparison of indirect hemagglutination and 51chromium release tests for detection of Herpes Simplex Virus type 1 and 2 antibodies in patients with recurrent Herpes infections.

Authors:  L Kesavalu; P Seth
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.